Back to Search
Start Over
Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease.
- Source :
-
Clinical and experimental nephrology [Clin Exp Nephrol] 2015 Apr; Vol. 19 (2), pp. 247-53. Date of Electronic Publication: 2014 May 13. - Publication Year :
- 2015
-
Abstract
- Background/aims: Type 2 diabetic kidney disease (DKD) is frequently accompanied by uncontrollable hypertension due to the sodium sensitivity inherent in DKD and to diuretic-resistant edema. In general, diuretics are effective in treating this condition, but thiazide diuretics are thought to be innocuous in advanced chronic kidney disease (CKD). We examined the renoprotective effects of combination therapy with thiazides and loop diuretics in type 2 DKD patients with CKD stage G4 or G5.<br />Methods: This study included 11 patients with type 2 DKD and an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m(2) who were suffering from severe edema even with loop diuretics. Each patient received additional hydrochlorothiazide (HCTZ) therapy, which was continued for more than 12 months. We examined clinical parameters including blood pressure (BP), proteinuria, and eGFR before and after the addition of HCTZ.<br />Results: Patients received a 13.6 ± 3.8 mg/day dose of HCTZ in addition to loop diuretics (azosemide: 120 mg/day in 6 cases, 60 mg/day in 3 cases and furosemide: 80 mg/day in 1 case, 120 mg/day in 1 case). Side effects of HCTZ were not observed in all patients. After the addition of HCTZ therapy, systolic and diastolic blood pressures (S-BP, D-BP) as well as proteinuria significantly decreased (S-BP: at 6 months, p < 0.05 and 12 months, p < 0.01 vs. 0 month, D-BP: at 12 months, p < 0.05 vs. 0 month, proteinuria: at 6 months, p < 0.05 and 12 months, p < 0.01 vs. 0 month). The annual decline in eGFR was not significantly different before and after HCTZ therapy (-7.7 ± 8.5 and -8.4 ± 4.8 mL/min/1.73 m(2)/year, respectively).<br />Conclusion: Our findings suggest that the combination of HCTZ and loop diuretics improves BP levels, and decreases proteinuria even in advanced stage type 2 DKD patients with severe edema. The addition of HCTZ therapy was not found to negatively affect the change in eGFR in the present study.
- Subjects :
- Aged
Aged, 80 and over
Antihypertensive Agents therapeutic use
Blood Pressure
Diabetic Nephropathies physiopathology
Drug Therapy, Combination
Female
Furosemide therapeutic use
Glomerular Filtration Rate
Humans
Hypertension etiology
Male
Middle Aged
Proteinuria drug therapy
Proteinuria etiology
Retrospective Studies
Sulfanilamides therapeutic use
Diabetes Mellitus, Type 2 complications
Diabetic Nephropathies complications
Diuretics therapeutic use
Edema etiology
Hydrochlorothiazide therapeutic use
Hypertension drug therapy
Renal Agents therapeutic use
Sodium Potassium Chloride Symporter Inhibitors therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1437-7799
- Volume :
- 19
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Clinical and experimental nephrology
- Publication Type :
- Academic Journal
- Accession number :
- 24821289
- Full Text :
- https://doi.org/10.1007/s10157-014-0981-2